Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, announced that it has released its first Environmental, Social and Governance (ESG) Report. The report highlights the progress Clario made across a range of metrics between 2020 and 2021, as well as ambitious targets for growth and improvement in the coming years.

The ESG Report outlines the findings of Clario’s materiality analysis, which helped the company prioritize its efforts based on where it could make the most impact. Based on the findings, Clario built an action plan to drive results in the following areas:

  • Increasing diversity, equity and inclusion (DE&I) in the workforce and in clinical trials by recruiting and developing diverse talent, accelerating pay equity, expanding Employee Resource Groups (ERGs) and working with customers and partners to improve patient diversity in clinical trials with DCT technologies.
  • Minimizing carbon footprint and waste production by monitoring and reporting scope 1, 2 and 3 greenhouse gas (GHG) emissions and energy usage and reducing packaging and shipping volumes.
  • Leading transformation within local communities through corporate giving initiatives such as the donation of end-of-life devices (over 2,000 devices donated in 2021), ensuring ethical compliance and data security and working with a sustainable supply chain by vetting suppliers and reviewing their sustainability and diversity programs. Read more here.